• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Veracyte Inc.

    6/12/24 4:57:30 PM ET
    $VCYT
    Medical Specialities
    Health Care
    Get the next $VCYT alert in real time by email
    S-8 1 vcyt-06122024xs8.htm S-8 Document

    As filed with the Securities and Exchange Commission on June 12, 2024
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ____________________
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    ____________________
    VERACYTE, INC.
    (Exact name of registrant as specified in its charter)
    Delaware
    (State or other jurisdiction of
    incorporation or organization)
    20-5455398
     (I.R.S. Employer
    Identification No.)
    6000 Shoreline Court, Suite 300
    South San Francisco, California
    (Address of Principal Executive Offices)
    94080
    (Zip Code)
    Veracyte, Inc. 2023 Equity Incentive Plan
    (Full title of the plan)
    Marc Stapley
    Chief Executive Officer
    6000 Shoreline Court, Suite 300
    South San Francisco, California
    (Name and address of agent for service)
    (650) 243-6300
    (Telephone number, including area code, of agent for service)
    Copies to:
    Ran Ben-Tzur, Esq.
    Chelsea Anderson, Esq.
    Fenwick & West LLP
    730 Arizona Avenue, 1st Floor
    Santa Monica, California 90401
    Annie McGuire Esq.
    Executive Vice President and
    General Counsel
    Veracyte, Inc.
    6000 Shoreline Court, Suite 300
    South San Francisco, California 94080
    (650) 243-6300

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer☒Accelerated filer☐
    Non-accelerated filer☐Smaller reporting company☐
    Emerging growth company☐





    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐






    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

    Pursuant to General Instruction E of Form S-8, Veracyte, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (the “Commission”) to register 5,000,000 additional shares of the Registrant’s common stock (the “Share Increase”) available for issuance under the Registrant’s 2023 Equity Incentive Plan (the “2023 Plan”). At the Registrant’s Annual Meeting of Stockholders held on June 12, 2024, the Registrant’s stockholders, among other things, approved the Share Increase under the 2023 Plan.

    In accordance with General Instruction E of Form S-8, and only with respect to the common stock issuable under the 2023 Plan, this Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statements on Form S-8 filed with the Commission on October 30, 2013 (File No. 333-191992), March 30, 2015 (File No. 333-203097), March 14, 2016 (File No. 333-210185), March 2, 2017 (File No. 333-216388), February 28, 2018 (File No. 333-223292), February 25, 2019 (File No. 333-229848), February 25, 2020 (File No. 333-236630), February 22, 2021 (File No. 333-253363), March 1, 2022 (File No. 333-263116) and March 1, 2023 (File No. 333-270147), in each case as amended, to the extent not superseded hereby. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of Form S-8 has been omitted from this Registration Statement

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.
    The following documents filed by the Registrant with the Commission are hereby incorporated by reference in this Registration Statement:
    (a)    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on February 29, 2024.
    (b)    All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above (other than the portions of these documents not deemed to be filed); and
    (c)    The description of the Registrant’s Common Stock contained in Registrant’s registration statement on Form 8-A, filed on October 28, 2013 pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.2 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on February 29, 2024.

    In addition, all documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (excluding any portions thereof furnished by the Registrant, including information furnished under Item 2.02 and Item 7.01 and any exhibits relating to Item 2.02 or Item 7.01 furnished under Item 9.01 of Form 8-K and any certification required by 18 U.S.C. § 1350), subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.





    Item 8.Exhibits.
    The following exhibits are filed herewith:

    Incorporated by Reference
    Exhibit No.DescriptionFormFile No.ExhibitFiling DateFiled Herewith
    4.1
    Restated Certificate of Incorporation of the Registrant
    8-K001-361563.26/9/2023
    4.2
    Amended and Restated Bylaws of the Registrant
    8-K001-361563.36/9/2023
    4.3
    Form of Common Stock Certificate
    S-1/A333-1912824.110/15/2013
    5.1
    Opinion of Fenwick & West LLP
    X
    23.1
    Consent of Independent Registered Public Accounting Firm
    X
    23.2
    Consent of Fenwick & West LLP (included in Exhibit 5.1)
    X
    24.1
    Power of Attorney (contained on signature page hereto).
    X
    99.1
    2023 Equity Incentive Plan, as amended
    DEF 14-A001-36156Appendix A4/25/2024
    99.2
    Form of agreements under the 2023 Equity Incentive Plan
    S-8 POS333-27014799.66/8/2023
    107.1
    Filing Fee Table
    X


    Item 9.Undertakings.
    (a) The undersigned Registrant hereby undertakes:
    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and
    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;
    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.
    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.




    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.





    SIGNATURES
    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of South San Francisco, State of California, on the 12th day of June, 2024.
    VERACYTE, INC.
    By:/s/ MARC STAPLEY
    Marc Stapley
    Chief Executive Officer and Director

    POWER OF ATTORNEY

    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Marc Stapley and Rebecca Chambers and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement on Form S-8, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    SignatureTitleDate
    /s/ MARC STAPLEYChief Executive Officer and Director
    (Principal Executive Officer)
    June 12, 2024
    Marc Stapley
    /s/ REBECCA CHAMBERSChief Financial Officer
    (Principal Financial Officer)
    June 12, 2024
    Rebecca Chambers
    /s/ JONATHAN WYGANTChief Accounting Officer (Principal Accounting Officer)June 12, 2024
    Jonathan Wygant
    /s/ ROBERT S. EPSTEINChairperson and DirectorJune 12, 2024
    Robert S. Epstein
    /s/ ELIAV BARR, M.D.DirectorJune 12, 2024
    Eliav Barr, M.D.
    /s/ MUNA BHANJIDirectorJune 12, 2024
    Muna Bhanji
    /s/ KARIN EASTHAMDirectorJune 12, 2024
    Karin Eastham
    /s/ JENS HOLSTEINDirectorJune 12, 2024
    Jens Holstein
    /s/ EVAN JONESDirectorJune 12, 2024
    Evan Jones


    Get the next $VCYT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VCYT

    DatePrice TargetRatingAnalyst
    12/2/2025$48.00Underweight
    Morgan Stanley
    10/20/2025$40.00Hold
    Canaccord Genuity
    3/20/2025$45.00Buy
    Craig Hallum
    12/5/2024$38.00 → $37.00Buy → Neutral
    Goldman
    11/15/2024$50.00Outperform
    Wolfe Research
    10/16/2024$43.00Buy
    UBS
    10/10/2024$40.00Buy
    Guggenheim
    2/23/2024$30.00 → $33.00Buy
    Needham
    More analyst ratings

    $VCYT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, General Counsel Mcguire Annie sold $463,204 worth of shares (10,739 units at $43.13), decreasing direct ownership by 14% to 67,760 units (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    12/17/25 4:35:10 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Director Eastham Karin exercised 20,000 shares at a strike of $7.77 and sold $908,923 worth of shares (20,000 units at $45.45) (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    12/8/25 4:34:30 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Chief Scientific & Med Officer Febbo Phillip G. covered exercise/tax liability with 2,955 shares, decreasing direct ownership by 3% to 89,486 units (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    12/4/25 7:44:29 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Veracyte with a new price target

    Morgan Stanley resumed coverage of Veracyte with a rating of Underweight and set a new price target of $48.00

    12/2/25 8:36:20 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Canaccord Genuity initiated coverage on Veracyte with a new price target

    Canaccord Genuity initiated coverage of Veracyte with a rating of Hold and set a new price target of $40.00

    10/20/25 8:47:51 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Craig Hallum initiated coverage on Veracyte with a new price target

    Craig Hallum initiated coverage of Veracyte with a rating of Buy and set a new price target of $45.00

    3/20/25 7:42:48 AM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Veracyte Inc.

    SCHEDULE 13G/A - VERACYTE, INC. (0001384101) (Subject)

    2/5/26 1:40:12 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - VERACYTE, INC. (0001384101) (Filer)

    1/12/26 6:05:03 AM ET
    $VCYT
    Medical Specialities
    Health Care

    SEC Form 144 filed by Veracyte Inc.

    144 - VERACYTE, INC. (0001384101) (Subject)

    12/5/25 4:26:29 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/motsphxv. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://inv

    2/4/26 5:15:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

    Grew full-year revenue to between $515 million and $517 million, an increase of 16% Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. Preliminary Unaudited Financial Results For the fourth quarter ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report: Total revenue of between $138 million and $140 million, an increase of between 16% and 18% Testing revenue of between $134 million and $136 million, an increase of between 19% and 21% Testing volume of approximately 45,500, an increase of 16% For the ful

    1/11/26 4:30:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Smart Oncology: 5 Stocks Chasing the $317B Prize

    Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Dec. 31, 2025 /PRNewswire/ -- The precision oncology market surged to $139.4 billion in 2025 and is racing toward $317.5 billion by 2035[1], driven by a fundamental shift in cancer treatment philosophy. Biomarker-guided therapy selection now enables oncology pharmacists and clinicians to match treatments to tumor-specific characteristics rather than relying on blind, one-size-fits-all protocols[2]. This convergence of diagnostic precision and therapeutic targeting defines the investment thesis for Oncolytics Biotech Inc. (NASDAQ:ONCY), Exact Sciences Corp. (NASDAQ:EXAS), Veracyte, Inc. (NASDAQ:VCYT),

    12/31/25 7:25:00 AM ET
    $EXAS
    $HOLX
    $ONCY
    Medical Specialities
    Health Care
    Medical Electronics
    Biotechnology: Pharmaceutical Preparations

    $VCYT
    Leadership Updates

    Live Leadership Updates

    View All

    Veracyte Set to Join S&P SmallCap 600

    NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE:TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners LLC will acquire Triumph Group in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 29, 2025 S&P SmallCap 600 Addition Veracyte VCYT Health Care July 29, 2025 S&P SmallCap 600 Deletion Triumph Group TGI Industrials For more information about S&P Dow Jones Indices,

    7/24/25 5:58:00 PM ET
    $SPGI
    $TGI
    $VCYT
    Finance: Consumer Services
    Finance
    Aerospace
    Industrials

    Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904531409/en/New Veracyte board member Brent Shafer. (Photo: Business Wire) "We are thrilled to welcome Brent and Tom to our board," said Marc Stapley, Veracyte's chief executive officer. "They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board's mix of backgrounds and expertise." Mr. Shafer brings over 40 years of experience ac

    9/4/24 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer

    Veracyte, Inc. (NASDAQ:VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte's global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer. He will report to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927846710/en/Veracyte Names Phillip G. Febbo, M.D., a

    9/27/23 9:00:00 AM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Financials

    Live finance-specific insights

    View All

    Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/motsphxv. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://inv

    2/4/26 5:15:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Announces Third Quarter 2025 Financial Results

    Grew total revenue to $131.9 million and testing revenue to $127.8 million, representing increases of 14% and 17% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. "We delivered another outstanding quarter of testing revenue growth and adjusted EBITDA margin expansion, enabling us to raise both our revenue and profitability guidance," said Marc Stapley, Veracyte's chief executive officer. "We continue to advance our mission of transforming cancer care by generating high-quality evidence and clinical insights tha

    11/4/25 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025 after the close of market on Tuesday, November 4, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/kcexjtb4. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.

    10/15/25 5:31:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Veracyte Inc.

    SC 13G - VERACYTE, INC. (0001384101) (Subject)

    11/12/24 9:30:49 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veracyte Inc.

    SC 13G/A - VERACYTE, INC. (0001384101) (Subject)

    11/8/24 10:41:07 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veracyte Inc.

    SC 13G/A - VERACYTE, INC. (0001384101) (Subject)

    10/2/24 2:12:30 PM ET
    $VCYT
    Medical Specialities
    Health Care